Back to pipeline
CSE1034

CSE -1034 is a novel Antibiotic Adjuvant Entity (AAE) consisting of beta-lactam antibiotic (Ceftriaxone) + beta-lactamase inhibitor (Sulbactam) + a non-antibiotic adjuvant compound/Antibiotic Resistance Breaker (RD-1034) active against ESBL/ESBL + MBL producing gram-negative bacteria. Currently, it has successfully completed Phase III double-blind study against meropenem and has proven non-inferiority to meropenem in cUTI patients.


POTENTIAL ACTIVITY AGAINST

WHO priority pathogens

ESKAPE pathogens

Back to pipeline
VRP-032

VRP - 032 is a biomimetic antimicrobial infusion therapy indicated for septicemia and XDR resistant pathogens. Currently, this showed efficacy against resistant pathogens bacteria, virus, fungi, and various other faulty proteins.


POTENTIAL ACTIVITY AGAINST

WHO priority pathogens

ESKAPE pathogens

Back to pipeline
VRP-001

VRP-001 is an oral antibiotic adjuvant entity (AAE) based on stealth targeted nanoparticle (STN) technology. The product is designed to meet the unmet need of shifting an MDR patient from IV to oral therapy in infections caused by ESBL (Extended Spectrum Beta-lactamases) and MBL (Metallo-beta-lactamases) producing gram-negative pathogens (such as E.coli, A.baumannii, P.aeruginosa, and K.pneumoniae).


POTENTIAL ACTIVITY AGAINST

WHO priority pathogens

ESKAPE pathogens

Back to pipeline
VRT001-M

VRT 001-M is an oral antibiotic based on stealth targeted nanoparticle (STN) technology. The product is designed to meet the unmet need of shifting patients from IV to oral therapy in infections caused by both aerobic Gram-positive and aerobic Gram-negative bacteria, and also covers common anaerobes. Proposed Indication: meningitis, intraabdominal infection, severe skin infections, pneumonia, sepsis, and anthrax.


POTENTIAL ACTIVITY AGAINST

WHO priority pathogens

ESKAPE pathogens

Back to pipeline
VRT001-C

VRT 001-C is an oral antibiotic based on stealth targeted nanoparticle (STN) technology. The product is designed to meet the unmet need of shifting patients from IV to oral therapy in infections caused by both aerobic Gram-positive and aerobic Gram-negative bacteria, and also covers some anaerobes. Proposed Indication: complicated and uncomplicated urinary tract infections, lower respiratory tract infections, skin, soft tissue, bone and joint infections, bacteraemia/septicaemia, and paediatric meningitis


POTENTIAL ACTIVITY AGAINST

WHO priority pathogens

ESKAPE pathogens

Back to pipeline
VRT001-V

VRT 001-V is an oral antibiotic based on stealth targeted nanoparticle (STN) technology. The product is designed to meet the unmet need of shifting patients from IV to oral therapy in infections caused by both gram-positive cocci and gram-negative cocci. Proposed Indication: serious staphylococcal infection, Streptococcal endocarditis, acute staphylococcal ileocolitis.


POTENTIAL ACTIVITY AGAINST

WHO priority pathogens

ESKAPE pathogens

Back to pipeline
VRP-1620

VRP 1620 is a novel linear analog endothelin B receptor agonist which dilates the blood vessels surrounding tumor and thereby provides selective transient vasodilation which when used in adjunct with Sonomammography increases specificity and PPV without affecting sensitivity. This would be beneficial for theranostics delivery simultaneously to the tumor, thereby enhancing the chances of survival in cancer patients and will help eliminate false positive and false negatives.


Back to pipeline
VRP-007

VRP 007 is a novel target-based drug delivery for cancer treatment derived from a platform technology with a novel concept of triple conjugate i.e., Drug-Protein - Polymer -Conjugate (DPPC). This technology helps in targeting active drug moieties to affected site/organs in chronic disease therapies associated with cancer and receptor diseases. This technology has the potential to conjugate a wide range of drugs (physiochemically different) with better selectivity to a defined population of affected organ and reducing the drug-related side effects and toxicities which are associated in conventional therapies. It targets cell signaling proteins/receptors present in the tumor cell.


Back to pipeline
VRT002-D

VRT002-D is a novel target-based docetaxel delivery for cancer treatment derived from a platform technology with a novel concept of triple conjugate i.e., Drug-Protein- Polymer-Conjugate (DPPC). This technology helps in targeting active drug moieties to affected site/organs in chronic disease therapies associated with cancer and receptor diseases. This technology has the potential to conjugate a wide range of drugs (physiochemically different) with better selectivity to a defined population of affected organ and reducing the drug-related side effects and toxicities which are associated in conventional therapies. Indications: breast, lung, prostate, stomach, and head/neck cancer.


Back to pipeline
VRT002-P

VRT 002-P is a novel target-based Pemetrexed delivery for cancer treatment derived from a platform technology with a novel concept of triple conjugate i.e., Drug-Protein- Polymer-Conjugate (DPPC). This technology helps in targeting active drug moieties to affected site/organs in chronic disease therapies associated with cancer and receptor diseases. This technology has the potential to conjugate a wide range of drugs (physiochemically different) with better selectivity to a defined population of affected organ and reducing the drug-related side effects and toxicities which are associated in conventional therapies. Indications: Non-small cell lung cancer, Malignant Pleural Mesothelioma.


Back to pipeline
VRT002-G

VRT 002-G is a novel target-based Gemcitabine delivery for cancer treatment derived from a platform technology with a novel concept of triple conjugate i.e., Drug-Protein- Polymer-Conjugate (DPPC). This technology helps in targeting active drug moieties to affected site/organs in chronic disease therapies associated with cancer and receptor diseases. This technology has the potential to conjugate a wide range of drugs (physiochemically different) with better selectivity to a defined population of affected organ and reducing the drug-related side effects and toxicities which are associated in conventional therapies. Indications: Ovarian cancer, Breast cancer, Non-small cell lung cancer, Pancreatic cancer.


Back to pipeline
VRP-1013

VRP-1013 is an integrated natural medicine designed to provide an unmatched natural solution for chronic pain associated with body aches, headaches, dental pain, postoperative pain, pain in connection with colds & post-traumatic muscle pain.


Back to pipeline
VRP-1010

VRP-1010 is a chewable tablet of effective and potent polyherbal extract. It is designed to provide complete cure & protection from liver-associated diseases and strengthen liver functionality.


Back to pipeline
VRP-1012

VRP-1012 is an innovative combination of pure natural essential oil with a natural ointment base. The unique stick form of the balm is easy to use & carry. It is topical preparation to relieve headache, neck pain and shoulder stiffness.


Back to pipeline
VRP-029

RP-029 is a biodegradable and biocompatible natural polymer based Hemostatic gel. This is easily usable by a layman "fire and forget missile" technology. It prolongs the "golden period" for hospitalization from less than 30 minutes to 4-6 h and thereby increases the chances of survival after traumatic injury. It targets ionic interaction between RBC and positively charged quaternary ammonium ion of chitosan. It can be used along with other hemostatic wound sealants.


Back to pipeline
VRP-030

VRP-030 is a biodegradable and biocompatible natural polymer based Hemostatic product with advanced clotting technology which can stop bleeding in less than a minute. This is easily usable by a layman ("fire and forget missile" technology, just press for a minute on the bleeding area and remove with water when reaching the hospital) and stops the severe bleeding within minutes which is crucial for saving a life in a hemorrhagic situation. It prolongs the "golden period" for hospitalization from less than 30 minutes to 4-6 h and thereby increases the chances of survival after traumatic injury. It targets ionic interaction between RBC and positively charged quaternary ammonium ion of chitosan


Back to pipeline
VRP-031

VRP-031 is a biodegradable and biocompatible natural polymer based Hemostatic product with advanced clotting technology which can stop bleeding in less than a minute. This is easily usable by a layman ("fire and forget missile" technology, just apply once on the bleeding area and it stops the severe bleeding within minutes) which is crucial for saving a life in a hemorrhagic situation. It prolongs the "golden period" for hospitalization from less than 30 minutes to 4-6 h and thereby increases the chances of survival after traumatic injury. It targets ionic interaction between RBC and positively charged quaternary ammonium ion of chitosan.


Back to pipeline
Ampucare/Septiloc

Ampucare/Septiloc is a Novel Topical Herbal Wound Healing Product for Chronic Non-Healing Wounds. Winner of Best innovation award – 2010 under India Innovation Growth Program organized by the Department of Science & Technology (DST), India, Lockheed Martin, USA, FICCI, India.


Back to pipeline
TROIS

TROIS is a powerful nanotech emulsion with a unique blend of essential oils of natural origin for multi-action topical application, which has potent analgesic & anti-inflammatory effects. Being a nanotech emulsion TROIS is absorbed quickly into the skin to give better, quicker & long lasting relief from pain. TROIS emulsion is non-greasy, non-Irritant, well tolerated and absorbed within seconds. TROIS is available as 50ml in specially designed, easy to handle glass bottle with Soft Roll-On. "Soft Roll-On" over glass bottle of TROIS makes emulsion to spread easily and quickly on the applied area by keeping hands neat and clean.


Copyright © 2019 VMRCINDIA All Rights Reserved last Update: 17 July 2020